Press Releases
PhoreMost enters multi-project drug discovery collaboration with Otsuka Pharmaceutical
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a multi-project collaboration with Otsuka Pharmaceutical Co., the world-leading pharmaceutical company dedicated to the research and development of highly-innovative drugs and diagnostics....
Press Releases
Bormioli pharma unveils at Pharmapack Europe new products and services
Bormioli Pharma, leading global producer in the pharma packaging market, will attend Pharmapack Europe, one of the leading European events dedicated to pharmaceutical packaging, drug delivery, medical devices and machinery, connecting pharma packaging producers and clients. The trade fair...
Press Releases
Aptar Pharma’s Nasal Unidose Device Approved by US FDA for New Nasal Seizure Rescue Treatment
Aptar Pharma, a global leader in drug delivery systems, services and active packaging solutions, announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for...
Clinical Trials
Greenphire Expands ConneX Global Travel Solution to Further Support Clinical Trial Participation and Retention Worldwide
Greenphire, the global leader in financial software for clinical trials, announced that it has expanded its ConneX global travel solution to include additional in-market support and visa fulfillment services.
Used by more than 40 pharmaceutical companies (7 of the top...
Clinical Trials
VBI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac Meets Primary and Secondary Endpoints
VBI Vaccines Inc. (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported top-line data from CONSTANT, the second pivotal Phase 3 study, assessing lot-to-lot manufacturing consistency of Sci-B-Vac®, the company’s trivalent hepatitis B (HBV) vaccine,...
Clinical Trials
Novo Seeds Portfolio Company HepaRegeniX GmbH secures Series B Financing in excess of EUR 11 Million
Novo Seeds, the early stage investment and company creation team of Novo Holdings, announced that its portfolio company HepaRegeniX GmbH, a preclinical stage company developing a novel therapy for the treatment of acute and chronic liver diseases has successfully...
Press Releases
Galen Announces Completion of Multi-Million Pound POA Pharma Acquisition
Galen, the privately owned global pharmaceutical sales and marketing company, announced the completion of a multi-million pound acquisition and takeover of boutique healthcare company, POA Pharma. The move enables Galen to significantly expand its global reach and product portfolio...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.